Narcotic Antagonists
Research News and Information

Monday, November 23, 2009

Dry eye reversal and corneal sensation restoration with topical naltrexone in diabetes mellitus.

30 Oct 2009 OBJECTIVE: To determine if topical application of naltrexone hydrochloride (NTX), an opioid antagonist, restores tear production and corneal sensation in rats with diabetes mellitus. METHODS: Type 1 diabetes was induced with streptozotocin in rats. ... Read more...

An ultra-low dose of naloxone added to lidocaine or lidocaine-fentanyl mixture prolongs axillary brachial plexus blockade.

30 Oct 2009 INTRODUCTION: In this prospective, randomized, double-blind study, we evaluated the effect of an ultra-low dose of naloxone added to lidocaine and fentanyl mixture on the onset and duration of axillary brachial plexus block. METHODS: One hundred ... Read more...

Acute methadone treatment reduces myocardial infarct size via the delta-opioid receptor in rats during reperfusion.

30 Oct 2009 BACKGROUND: Methadone is an opioid agonist often given to manage acute and chronic pain. We sought to determine whether methadone compared with morphine dose dependently reduces myocardial infarct size (IS) and whether the mechanism is delta-opioid ... Read more...

Latest indexed articles for 'Narcotic Antagonists'

These are the very latest articles for this heading:

• Dry eye reversal and corneal sensation restoration with topical naltrexone in diabetes mellitus. 30 Oct 2009
• An ultra-low dose of naloxone added to lidocaine or lidocaine-fentanyl mixture prolongs axillary brachial plexus blockade. 30 Oct 2009
• Acute methadone treatment reduces myocardial infarct size via the delta-opioid receptor in rats during reperfusion. 30 Oct 2009
• Contribution of endogenous opioids to gonadal hormones-induced temporomandibular joint antinociception. 29 Sep 2009
• Naloxone, but not flupenthixol, disrupts the development of conditioned ejaculatory preference in the male rat. 29 Sep 2009
• The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence. 29 Sep 2009
• Effectiveness of community treatments for heroin and crack cocaine addiction in England: a prospective, in-treatment cohort study. 29 Sep 2009
• Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone. 29 Sep 2009
• The synergistic interaction between morphine and maprotiline after intrathecal injection in rats. 29 Sep 2009
• The peripheral antinociceptive effects of endomorphin-1 and kynurenic acid in the rat inflamed joint model. 29 Sep 2009
• Influence of the side chain next to C-terminal benzimidazole in opioid pseudopeptides containing the Dmt-Tic pharmacophore. 8 Sep 2009
• Emerging drugs for chronic constipation. 30 Aug 2009
• Long-term use of methylnaltrexone for the management of constipation in advanced cancer. 30 Aug 2009
• Effectiveness of two opioid antagonists in treating opioid-induced constipation. 30 Aug 2009
• Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers. 10 Aug 2009
• In brief: heat and transdermal fentanyl. 8 Aug 2009
• [Preventing weight gain in smoking cessation: there is no miracle solution] 3 Aug 2009
• Roles of opioid receptor subtypes in mediating alcohol-seeking induced by discrete cues and context. Aug 2009
• [Mechanisms of opioid-induced overdose: experimental approach to clinical concerns] Aug 2009
• Transient limb ischaemia remotely preconditions through a humoral mechanism acting directly on the myocardium: evidence suggesting cross-species protection. Aug 2009

See a longer list of these articles.

Technical information about 'Narcotic Antagonists'

Definition: Agents inhibiting the effect of narcotics on the central nervous system.

Registry Number: 0

Descriptor UI: D009292

Alternative terms: Narcotic Antagonists; Antagonists, Narcotic; Opioid Antagonists; Antagonists, Opioid;

Allowable Qualifiers: diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; administration & dosage; adverse effects; analysis; blood; cerebrospinal fluid; chemical synthesis; classification;

Tree Number: D27.505.696.543; D27.505.696.663.850.512; D27.505.954.427.550;

Technical Notes: DF: NARCOTIC ANTAG